LITTLE KNOWN FACTS ABOUT INTERLEUKIN-2 THERAPY.

It can be perfectly recognized that IL-2 is really a pleiotropic cytokine positioned for the crossroads of T cell activation and regulation. As a result, it is very important to engineer an IL-2 molecule that is biased in direction of effector cells bearing the intermediate affinity receptor, which include naïve and memory CD8+ T cells and NK cell